Systematic Review and Meta-analysis of the Benefit of Celecoxib in Treating Advanced Non-small-cell Lung Cancer

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2018 Aug 21

PMID 30122902

Citations 11

Authors

Lilan Yi

Wei Zhang

Hongman Zhang

Jie Shen

Jingwen Zou

Peng Luo

Jian Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The clinical benefit of a selective cyclooxygenase-2 inhibitor, celecoxib, combined with anticancer therapy in advanced non-small-cell lung cancer (NSCLC) remains unclear. A meta-analysis was performed to address the efficacy and safety of celecoxib in patients with advanced NSCLC.

Materials And Methods: Three databases, including PubMed, EMBASE, and the Cochrane Library, were systematically searched for available literature until March 1, 2018. Data on tumor response rates, one-year survival, overall survival, progression-free survival, and toxicities were extracted from the included randomized clinical trials. Subgroup analysis was carried out according to the line of treatment. Review Manager 5.3 software was applied to conduct the meta-analysis.

Results: A total of 7 randomized controlled trials involving 1,559 patients with advanced NSCLC were enrolled for analysis. The pooled overall response rate (ORR) of celecoxib added to systemic therapy was not significantly improved (risk ratio [RR] =1.14, 95% CI =0.96-1.35, =0.13). Additionally, no differences were observed between the celecoxib and placebo groups regarding 1-year survival (RR =0.99, 95% CI =0.88-1.12, =0.91). Subgroup analysis showed that adding celecoxib to the first-line treatment significantly improved the ORR (RR =1.21, 95% CI =1.01-1.44, =0.04) and partial response rate (RR =1.26, 95% CI =1.01-1.58, =0.04). The aggregated Kaplan-Meier analysis found no significant difference between celecoxib and placebo regarding the 5-year overall survival (median, 12.9 vs 12.5 months, =0.553) and 5-year progression-free survival (median, 7.4 vs 7.2 months, =0.641). The increased RR of leukopenia (RR =1.25, 95% CI =1.03-1.50) and thrombocytopenia (RR =1.39, 95% CI =1.11-1.75) indicated that celecoxib increased hematologic toxicities (grade ≥III). However, celecoxib did not increase the related risks of thrombosis or embolism (RR =1.26, 95% CI =0.66-2.39) and cardiac ischemia (RR =1.16, 95% CI =0.39-3.44).

Conclusion: Celecoxib had no benefit on survival indices for advanced NSCLC but improved the ORR of first-line treatment. Additionally, celecoxib increased the rate of hematologic toxicities without increasing the risk of cardiovascular events.

Citing Articles

COX-2 in lung cancer: Mechanisms, development, and targeted therapies.

Liu X, Zhang J, Sun W, Cao J, Ma Z Chronic Dis Transl Med. 2024; 10(4):281-292.

PMID: 39429482 PMC: 11483542. DOI: 10.1002/cdt3.120.

Role of body mass index and weight change in the risk of cancer: A systematic review and meta-analysis of 66 cohort studies.

Shi X, Deng G, Wen H, Lin A, Wang H, Zhu L J Glob Health. 2024; 14:04067.

PMID: 38547495 PMC: 10978059. DOI: 10.7189/jogh.14.04067.

Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis.

Hu T, Liu C, Yin X, Tang W, Yin L, Bai H BMC Gastroenterol. 2023; 23(1):281.

PMID: 37580670 PMC: 10426080. DOI: 10.1186/s12876-023-02918-w.

Decreased cyclooxygenase-2 associated with impaired megakaryopoiesis and thrombopoiesis in primary immune thrombocytopenia.

Zhuang X, Xu P, Ou Y, Shao X, Li Y, Ma Y J Transl Med. 2023; 21(1):540.

PMID: 37573325 PMC: 10423426. DOI: 10.1186/s12967-023-04389-9.

Tackling Surgical Morbidity and Mortality through Modifiable Risk Factors in Cancer Patients.

Lee B, Han H Nutrients. 2022; 14(15).

PMID: 35956284 PMC: 9370480. DOI: 10.3390/nu14153107.

References

Mudad R, Patel M, Margunato-Debay S, Garofalo D, Lal L . Comparative effectiveness and safety of -paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting. Lung Cancer (Auckl). 2017; 8:179-190. PMC: 5656340. DOI: 10.2147/LCTT.S139647. View

Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty G, Sharma S . Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem. 2001; 276(24):20809-12. PMC: 1471882. DOI: 10.1074/jbc.C100140200. View

Valcarcel M, Mendoza L, Hernandez J, Carrascal T, Salado C, Crende O . Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2. J Transl Med. 2011; 9:142. PMC: 3189126. DOI: 10.1186/1479-5876-9-142. View

Sandler A, Dubinett S . COX-2 inhibition and lung cancer. Semin Oncol. 2004; 31(2 Suppl 7):45-52. DOI: 10.1053/j.seminoncol.2004.03.045. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Zelenay S, van der Veen A, Bottcher J, Snelgrove K, Rogers N, Acton S . Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell. 2015; 162(6):1257-70. PMC: 4597191. DOI: 10.1016/j.cell.2015.08.015. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

Torre L, Siegel R, Jemal A . Lung Cancer Statistics. Adv Exp Med Biol. 2015; 893:1-19. DOI: 10.1007/978-3-319-24223-1_1. View

Koch A, Bergman B, Holmberg E, Sederholm C, Ek L, Kosieradzki J . Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer. 2011; 47(10):1546-55. DOI: 10.1016/j.ejca.2011.03.035. View

10.

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

11.

Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S . Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998; 58(17):3761-4. View

12.

Masferrer J, Koki A, Seibert K . COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci. 2000; 889:84-6. DOI: 10.1111/j.1749-6632.1999.tb08726.x. View

13.

Lorenz M, Slaughter H, Wescott D, Carter S, Schnyder B, Dinchuk J . Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. Exp Hematol. 1999; 27(10):1494-502. DOI: 10.1016/s0301-472x(99)00087-9. View

14.

Khuri F, Wu H, Lee J, Kemp B, Lotan R, Lippman S . Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 2001; 7(4):861-7. View

15.

Scagliotti G, de Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S . Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20(21):4285-91. DOI: 10.1200/JCO.2002.02.068. View

16.

Arnold M, Pandeya N, Byrnes G, Renehan P, Stevens G, Ezzati P . Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2014; 16(1):36-46. PMC: 4314462. DOI: 10.1016/S1470-2045(14)71123-4. View

17.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

18.

Mutter R, Lu B, Carbone D, Csiki I, Moretti L, Johnson D . A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res. 2009; 15(6):2158-65. DOI: 10.1158/1078-0432.CCR-08-0629. View

19.

Altorki N, Keresztes R, Port J, Libby D, Korst R, Flieder D . Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol. 2003; 21(14):2645-50. DOI: 10.1200/JCO.2003.07.127. View

20.

Dohadwala M, Batra R, Luo J, Lin Y, Krysan K, Pold M . Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem. 2002; 277(52):50828-33. PMC: 1471886. DOI: 10.1074/jbc.M210707200. View